XML 13 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenue:    
Total revenue $ 29,621 $ 46,803
Operating costs and expenses:    
Cost of goods sold $ 15,561 $ 3,962
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 95,692 $ 266,473
Selling, general and administrative 49,330 86,483
Restructuring charge 19,454 12,606
Total operating costs and expenses 180,037 369,524
Loss from operations (150,416) (322,721)
Interest and other, net    
Interest expense (8,247) (8,095)
Interest income and other income (expenses), net 5,296 7,594
Total interest and other, net (2,951) (501)
Loss from continuing operations before income taxes (153,367) (323,222)
Benefit from income taxes (269) (252)
Loss from continuing operations (153,098) (322,970)
Income from discontinued operations, net of tax 105,519 38,738
Net loss $ (47,579) $ (284,232)
Loss from continuing operations per share - basic $ (1.53) $ (3.32)
Loss from continuing operations per share - diluted (1.53) (3.32)
Income from discontinued operations per share - basic 1.05 0.4
Income from discontinued operations per share - diluted 1.05 0.4
Net loss per share - basic (0.48) (2.92)
Net loss per share - diluted $ (0.48) $ (2.92)
Weighted average number of common shares used to calculate net loss per share    
Basic 100,044 97,303
Diluted 100,044 97,303
License Revenue [Member]    
Revenue:    
Total revenue $ 0 $ 9,649
Development and Other Revenue [Member]    
Revenue:    
Total revenue 1,948 18,401
Drug Product Revenue, Net [Member]    
Revenue:    
Total revenue $ 27,673 $ 18,753